Cardiovascular complications in patients with diabetic nephropathy;Powikłania sercowo-naczyniowe u chorych z nefropatia cukrzycowa

Przeglad Kardiodiabetologinczny

Volumn 3, Issue 3, 2008, Pages 217-222

  Glowińska, Irena ^a   Małyszko, Jolanta ^a  

^a Samodzielny Publiczny Dzieci cy Szpital Kliniczny   (Poland)

Author keywords

Cardiovascular complications; Diabetes type 2; Diabetic nephropathy; Nephroprotection

Indexed keywords

ADVANCED GLYCATION END PRODUCT; DIPEPTIDYL CARBOXYPEPTIDASE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CORONARY ARTERY BYPASS GRAFT; DEATH; DIABETIC NEPHROPATHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART PROTECTION; HUMAN; KIDNEY FAILURE; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; QUALITY OF LIFE; RENAL PROTECTION; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 77953443646     PISSN: 18969666     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Engelgau MM, Narayan KM, Saaddine JB, Vinicor F. Addressing the burden of diabetes in the 21st century: better care and primary prevention. J Am Soc Nephrol 2003; 14 (7 Suppl 2): S88-S91.
2. Harvey JN. Trends in the prevalence of diabetic nephropathy in type 1 and type 2 diabetes. Curr Opin Nephrol Hypertens 2003; 12: 317-322.
3. Pavcov M, Knowler W, Bennett P, et al. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int 2006; 70: 1840-1846.
4. Mueller P, Rogus J, Cleary P, et al. Genetics of Kidneys in Diabetes (GoKinD) study: a genetics collection available for identifying genetic susceptibility factors for diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol 2006; 17: 1782-1790.
5. Mishra R, Emancipator S, Kern T, Simonson M. High glucose evokes an intrinsic proapoptotic signaling pathway in mesangial cells. Kidney Int 2005; 67: 82-93,
6. de Jongh R, Serne E, Ijzerman R, Stehouwer C. Microvascular function: a potential link between salt sensitivity, insulin resistance and hypertension. J Hypertens 2007; 25: 1887-1893.
7. de Boer I, Sibley S, Kestenbaum B, et al. Central obesity, incident microalbuminuria, and change in creatinine clearance in the epidemiology of diabetes interventions and complications study. J Am Soc Nephrol 2007; 18: 235-243.
8. Morales E, Valero M, Leon M, et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephro-pathies. Am J Kidney Dis 2003; 41: 319-327.
9. Saiki A, Nagayama D, Ohhira M, et al. Effect of weight loss using formula diet on renal function in obese patients with diabetic nephropathy. Int J Obes (Lond) 2005; 29: 1115-1120.
10. Efrati S, Zaidenstein R, Dishy V, et al. ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 2002; 40: 1023-1029.
11. Xue J, Frazier E, Herzog C, Collins A. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J Kidney Dis 2005; 45: 316-323.
12. Charytan D, Kuntz R, Mauri L, DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 49: 409-416.
13. Russo D, Palmiero G, De Blasio A, et al. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2004; 44: 1024-1030.
14. Rosas S, Mensah K, Weinstein R, et al. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005; 5: 1942-1947.
15. Charytan D, Kuntz R. Risks of coronary artery bypass surgery in dialysis-dependent patients - analysis of the 2001 National Inpatient sample. Nephrol Dial Transplant 2007; 22: 1665-1671.
16. Yasuda K, Kasuga H, Aoyama T, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol 2006; 17: 2322-2332.
17. Gerstein H, Riddle M, Kendall D, et al. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol 2007; 99 (12A): 34i-43i.
18. Gross J, de Azevedo M, Silveiro S, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care 2005; 28: 164-176.
19. Jacobsen P, Andersen S, Jensen B, Parving H. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol 2003; 14: 992-999.
20. Berl T, Hunsicker L, Lewis J, et al. Impact of achieved blood pressure on cardiovascular outcomes in the irbesartan diabetic nephropathy trial. J Am Soc Nephrol 2005; 16: 2170-2179.
21. Grundy S, Cleeman J, Merz C, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-239.
22. Han S, Kim C, Kim H, et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. J Am Soc Nephrol 2006; 17: 1362-1372.